Banner
ABOUT US

公司簡介

2024
Fund(Icon) Fund
01.31
The capital increase case for the year 112, with a fund of 75 million NTD, has been fully subscribed, and the capital increase base date is set on 1st February.
Pat.(Icon) Pat.
01.18
"Artificial Dressing and Its Application for Promoting Wound Healing" has successfully obtained approval for a new invention patent in Taiwan.
Pat.(Icon) Pat.
01.11
SIPSIP™ Foam, the AMS BioteQ wound dressing, has successfully obtained FDA registration.
2023
Info(Icon) Info
12.21
SIPSIP™ Foam successfully obtained the TFDA medical device approval.
Info(Icon) Info
10.11
Debuted SIPSIPᵀᴹ Series dressing at Medical Japan 2023 Tokyo.
RD(Icon) RD
10.03
Collaboration with Kaohsiung Medical University and Thailand's Chulalongkorn University for the development of inhibiting Dengue virus DENV-2 experiment.
Info(Icon) Info
09.18
Issued the first employee stock warrants in 2023.
RD(Icon) RD
04.10
Collaboration with Kaohsiung Medical University and Mahidol University (Thailand) to develop anti-avian influenza drugs.
2022
Info(Icon) Info
12.05
Setting up the Quality Management System (QMS).
2021
Info(Icon) Info
12.30
Setting up the Audit and Compensation Committees, and listing on the Emerging Stock Market.
Info(Icon) Info
12.20
Issued the first employee stock warrants for 10M (NTD) in 2021.
Info(Icon) Info
11.08
The stocks were entirely replaced without physical certificates.
Fund(Icon) Fund
09.13
Implemented a cash capital increment of 90M (NTD), leading to an augmented paid-in capital of 250M (NTD) subsequent to the increment.
Info(Icon) Info
09.13
IPO to Taipei Exchange: Stock Symbol 6864
RD(Icon) RD
07.21
Announced collaboration with National Taiwan University College of Medicine for testing YUAN-03 in prevention and treatment of SARS-CoV-2. At the effective dose of 75ppm, the virus inhibition rate is almost 100%.
RD(Icon) RD
04.14
Announced collaboration with the Institute of Biotechnology and Pharmaceutical Research, NHRI. Passed testing against HCoV-OC43 with 50ppm effective dose, achieving 100% virus inhibition rate.
2020
Fund(Icon) Fund
11.16
Implemented a cash capital increment of 80M (NTD), leading to an augmented paid-in capital of 160M (NTD) subsequent to the increment.
Fund(Icon) Fund
05.20
Awarded the subsidy for the project 'Development of Hydrogel Spray with Natural Antimicrobial High Polymer Material,' granted by the Ministry of Economic Affairs, under the SBIR P1 program.
Fund(Icon) Fund
02.17
Awarded the subsidy for the project 'Development of Feed Additive Using Edible Probiotic Fermentation Technology,' granted by the Ministry of Economic Affairs, under the SBIR S1 program.
2019
Fund(Icon) Fund
06.10
Awarded the subsidy for the project 'Development of Immune-Modulating Feed Additives Using Edible Probiotic Technology', granted by the Industrial Development Administration, Ministry of Economic Affairs, under the CITD program.
Info(Icon) Info
05.06
Formation of RD base in Southern Taiwan Science Park.
2018
Fund(Icon) Fund
11.19
Implemented a cash capital increment of 79.95M (NTD), leading to an augmented paid-in capital of 80M (NTD) subsequent to the increment.
Pat.(Icon) Pat.
11.01
Successfully transferred technology from National Chung Hsing University for the formulation and production method of Streptomyces Padanus PMS-702 for plant protection.
Info(Icon) Info
04.02
Formation of AMS BioteQ Co., Ltd.